Introduction

B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the abnormal expansion of CD5
+ B cells arrested in G 0 /G 1 phase of the cell cycle. 1 CLL cells fail to undergo apoptosis in vivo, but survive only few days in vitro. Besides bone marrow stromal cells, 'nurse-like' cells, and different chemokines and cytokines as interleukin 4 and tumor necrosis factor alpha (TNFa), engagement of the CD40 receptor by its ligand, CD40L, is thought to induce survival via the activation of NFkB. [2] [3] [4] [5] The survival of leukemic B cells is also enhanced by engagement of their surface immunoglobulins (sIg), usually of IgM subtype (sIgM). B-cell receptor (BCR) crosslinking was shown to promote cell survival by caspase inhibition, induction of NF-kB, and expression of antiapoptotic molecules like bcl-2. 6 The purpose of this study was to determine whether BCR crosslinking could be used to overcome the resistance of primary B-CLL cells toward transduction by recombinant adeno-associated virus (rAAV) vectors in order to enable the expression of immunostimulatory transgenes for cellular vaccination strategies. Recently, we have shown that B-CLL cells stimulated by cocultivation on CD40L-expressing feeder cells can be efficiently infected by rAAV vectors. 7 To avoid this time-consuming and laborious prestimulation step, we explored whether it could be replaced by the stimulation of B-CLL cells with antibodies directed against the sIg homodimer of the BCR. Here, using freshly isolated cells from patients with CLL, we demonstrate that BCR crosslinking allows upregulation of the primary AAV receptor, heparan sulfate proteoglycan (HSPG). This resulted in an efficient AAV transduction with functional expression of transgenes in primary B-CLL cells without the need for a stimulating CD40L-expressing feeder system, thus facilitating future vaccination efforts for B-CLL.
Results
Characterization of B-CLL samples by surface IgM (sIgM), CD38, and zeta-associated protein 70 (ZAP-70) expression
Freshly isolated CD5/CD19
+ cells from patients with established diagnosis of B-CLL were studied for the expression of sIg, CD38, and intracellular ZAP-70. The study population consisted of 20 patients (15 male, five female). The mean age of the study population was 60.8 years (s.e.m., 2.4 years) with a median age of 62 years. Eight patients presented with early disease (Binet stage A) and 12 with advanced disease (Binet stage B, n ¼ 7; Binet stage C, n ¼ 5). Clinical characteristics of the patients including cytogenetic analysis by FISH are summarized in Table 1 . Expression of sIgM, the most common sIg expressed on B-CLL cells, 8 and expression of CD38 and ZAP-70, two surrogate markers for the mutational status of the immunoglobulin gene (IgV H ), 9, 10 were analyzed in all patients being entered on this study. Normal B cells isolated from human tonsils (n ¼ 3) were also studied for sIgM, CD38, and ZAP-70. While expression of sIgM was seen in both B-CLL cells (range, 3-97.0%) and tonsillar B cells (range, 55-69%), CD38 (range, 0-38.0%) and ZAP-70 (range, 0-100%) molecules could only be detected in CLL samples.
HSPG upregulation on primary B-CLL cells after CD40L stimulation compared to BCR engagement
In the previous work, we have shown that AAV transduction of primary B-CLL cells is possible after stimulation of leukemic B cells by CD40L. 7 Besides induction of cell cycle progression, we hypothesized that activation of B-CLL cells by CD40L might induce an upregulation of the primary AAV receptor, HSPG. Therefore, HSPG expression was studied on B-CLL cells 48 h after cocultivation on CD40L-expressing HeLa/SF cells. As shown in Figure 1a, HSPG expression was examined in CLL samples after stimulation with anti-IgM antibodies (a-IgM) at different concentrations for 72 h. As shown in Figure 1b , after stimulation with a-IgM at a concentration of 10 mg/ml, a mean of 51.9% of cells expressed HSPG on their surface, while no significant expression was detectable without the use of a-IgM. A further increase of HSPG induction was seen using 100 mg/ml of a-IgM with a mean percentage of 82.4% HSPG-positive CLL cells. There was a saturation kinetics observed with a mean of 98.4% HSPG-positive cells at a high concentration of 200 mg/ml a-IgM. Therefore, for all further experiments a concentration of 100 mg/ml a-IgM was used.
Samples derived from B-CLL patients (Table 2) were examined for their HSPG expression before and after stimulation with a-IgM. 
AAV transduction of primary B-CLL cells after BCR engagement
Freshly isolated B-CLL cells were incubated with 100 mg/ ml a-IgM and rAAV coding for enhanced green fluorescent protein (EGFP) (AAV/EGFP) and/or CD40L (AAV/CD40L) was added (MOI 50). After 48 h, transgene expression was assessed by flow cytometric analysis. The median expression of EGFP (19 patients) and CD40L (14 patients) was 29.8% (range 0-54%) and 10% (range 0-58.5%), respectively, with a mean expression of 23.2% (s.e.m. 4.4%) and 17.0% (s.e.m. 5.3%), respectively ( Table 2 ). Transduction of B-CLL cells was significantly enhanced after treatment of leukemic cells by anti-sIg antibodies compared to unstimulated leukemic cells (mean: 21.8%, s.e.m. 7.0% versus mean: 1.2%, s.e.m. 0.6%) (P ¼ 0.0356). Transduction levels of EGFP and CD40L were not significantly correlated with expression levels of sIgM (P ¼ 0.561 and 0.713, respectively). Importantly, there was a significant correlation of HSPG expression after a-IgM stimulation and transduction efficiency using AAV/EGFP (P ¼ 0.0153) and AAV/ CD40L (P ¼ 0.0347), respectively. There was no correlation seen between transduction efficiency with AAV/ EGFP and AAV/CD40L, respectively, and clinical stage of disease (A versus B/C; P ¼ 0.174 and 0.105, respectively), sex (P ¼ 0.511 and 0.903, respectively) or age (continuous) (P ¼ 0.545 and 0.928, respectively).
Specificity of AAV transduction after BCR stimulation was controlled by the incubation of AAV-infected CLL samples by heparin, a soluble receptor analogue similar to HSPG. 11 As seen in Figure 2 , viral transduction of EGFP after BCR stimulation was significantly decreased by heparin (P ¼ 0.0001), resulting in background levels of EGFP expression (mean: 1.8%, s.e.m. 1.2%). As further control, CLL samples were unspecifically stimulated by antibodies directed against sIgA, which is rarely expressed on CLL cells: only 2.4% (s.e.m. 1.3%) of cells could be transduced by AAV/EGFP. Transgene expression after unspecific stimulation of the BCR was significantly inferior compared to AAV transduction after stimulation of the same samples with a-IgM (P ¼ 0.012).
Transgene expression after AAV/EGFP transduction in the context of BCR engagement was compared to rAAV transduction after stimulation of B-CLL cells by CD40L-expressing HeLa/SF cells. Based on different CLL samples studied (nos. 14-16), there was no significant difference detectable in the percentage of EGFP-expressing cells (feeder: mean of 32.7%, s.e.m. 11.1% versus a-IgM: mean of 34.1%, s.e.m. 1.6%; 
.6%).
Next, the same CLL samples were infected by a different rAAV serotype, that is, AAV serotype 1 (AAV-1), in contrast to the common AAV serotype 2 (AAV-2) used in other experiments. AAV-1 is known to enter target cells via so far unknown receptors excluding membranebound HSPGs. Infection by recombinant AAV-1 coding for EGFP (AAV-1/EGFP) together with a-IgM stimulation did not result in a transgene expression beyond the background level (data not shown).
Finally, we used an AAV mutant (RGD4C) that contains an Arg-Gly-Asp (RGD) peptide at a specific site of the AAV capsid, thus lacking the specific binding site for the HSPG receptor on target cells. 12 This mutant was able to infect HeLa cells (MOI 100) via a v b 5 integrins as shown previously, but did not infect B-CLL cells (patient nos. 14-16) with (mean 0.4%, s.e.m. 0.3%) or without (mean 3.8%, s.e.m. 3.0%) stimulation of the BCR (P ¼ 0.382).
ZAP-70 expression and transduction efficiency by rAAV after BCR engagement
High expression of ZAP-70 in B-CLL cells was shown to be associated with enhanced signal transduction via the BCR complex and a more aggressive clinical course. 13, 14 We asked whether the expression level of ZAP-70, an easily detectable indicator of an efficient signaling through the BCR, is predictive for the AAV transduction efficiency into an individual CLL sample after stimulation of the BCR. Based on 20 samples derived from patients with B-CLL (Tables 1 and 2 
Activation of B-CLL cells after AAV/CD40L gene transfer
Since CD40L, a critical molecule for T-cell activation, is downregulated on T cells in patients with CLL and this defect was shown to be corrected by gene transfer of CD40L into leukemic B cells, we wanted to investigate the functionality of B-CLL cells after AAV/CD40L transduction in combination with BCR ligation. 7, [15] [16] [17] To prove that CD40L-transduced CLL cells were activated and become efficient antigen-presenting cells, expression of the costimulatory molecule CD80 was measured before and 120 h after infection with AAV/CD40L. CD80 expression could be induced from a mean of 0.1% (s.e.m. 0.1%) to 17.4% (s.e.m. 4.7%) and was significantly higher in comparison to uninfected control CLL cells (P ¼ 0.0076). Primary CLL cells transduced with wtAAV did not result in any upregulation of CD80 (mean 0.5%, s.e.m. 0.3%) (Figure 4a) .
It was previously shown that transduction with AAV/ CD40L based on feeder-stimulated CLL cells resulted in the upregulation of CD80 also on noninfected bystander leukemia B cells. 7, 15 This transactivation capacity of BCR-stimulated and AAV/CD40L-infected CLL cells was also assessed. Transduced CLL cells were labeled with a green fluorescent dye (CellTracker) and used as stimulator cells for equal numbers of nonlabeled CLL B cells derived from the same patient. Uninfected nonlabeled bystander CLL cells were induced to express CD80 after cocultivation with CD40L-transduced CLL cells (mean 5.5%, s.e.m. 1.3%), but not after coincubation with mock-infected (wtAAV) control CLL cells (mean 0.5%, s.e.m. 0.3%; P ¼ 0.0826) (Figure 4b ).
Discussion
The results presented demonstrate for the first time that gene transfer by rAAV into B-CLL cells can be markedly improved by engagement of the BCR. For ex vivo rAAV-mediated gene transfer in CLL cells, this proce- Table 2 ) were stimulated with 100 mg/ml a-IgM and infected with AAV/ EGFP (MOI 50
dure allows to replace a time-consuming stimulation process involving the coculture of a feeder cell line transfected with CD40L. Compared to previously published transduction data using the same AAV constructs in the context of feeder stimulation of CLL cells, we achieved similar transduction efficiencies for rAAV after BCR ligation and feeder stimulation. 7, 18 More importantly, we could elucidate a mechanism underlying the phenomenon that AAV transduction in B-CLL cells can be enhanced after BCR crosslinking: the primary AAV receptor, HSPG, was upregulated by BCR engagement. Recently, it was shown that activation of the BCR induces a strong transient expression of HSPGs on human tonsillar B cells, while malignant B cells were not studied. 19 HSPGs are critical regulators of growth and differentiation of epithelial and connective tissues for which AAV has a specific tropism. [20] [21] [22] [23] [24] Moreover, HSPGs function as coreceptors promoting cytokine signaling in normal B cells in the context of antigen-specific B-cell differentiation. Besides activation of the BCR, CD40 was shown to control the expression of HSPGs on tonsillar B cells. 19 We provide data that AAV transduction in the context of activation of CLL cells by CD40L-expressing feeder cells is regulated by HSPG expression. Therefore, different signals, that is, stimulation of the BCR and the CD40 receptor on human B-CLL cells, result in the induction of HSPGs on leukemic B cells. On a molecular level, the synergy between CD40 and the B-cell antigen receptor was demonstrated in normal B cells through cooperative signaling by TNF receptor-associated factor 2. Table 1 ) was detected before and 120 h after AAV/CD40L transduction (MOI 50) in combination with a-IgM (100 mg/ml) stimulation. CD80 expression was controlled on uninfected or wtAAV-infected CLL cells being stimulated with a-IgM (a). Uninfected nonlabeled bystander CLL cells (nos. 14-16) were assessed for CD80 expression 
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HSPGs were previously shown to be involved in integrin triggering and adhesion to endothelial cells during the process of extravasation of activated leukemic cells. 26 Transmembrane proteoglycans were proven to be essential for some NHLs, including CLL, to ensure a required connection to the microenvironment. 27 It can be speculated that integrin-mediated B-cell adhesion and migration is established by hepatocyte growth factor, which was shown to be crucial for HSPG binding in human tonsillar B cells. 19 Another interesting candidate would be stromal cell-derived factor (SDF)-1a, 28 although at least on human tonsillar B cells no interaction with HSPGs was shown. On the other hand, it was demonstrated that proteoglycans can establish an SDF-1 gradient in the subendothelial matrix guiding migrating hematopoietic progenitor cells into the bone marrow. 29 There is some additional evidence in the literature that HSPG induction is possible after the activation of malignant B cells: it was reported that the addition of lipopolysaccharide (LPS) to Daudi cells, a B-cell leukemia cell line, resulted in increased synthesis of heparan sulfate. 30 BCR crosslinking and LPS stimulation trigger both similar signaling molecules, that is, activation of NF-kB in B cells. 31 An alternative mechanism facilitating AAV transduction in B-CLL cells after BCR engagement that has to be discussed is an induction of S phase of the cell cycle resulting in an enhanced cell survival of B-CLL cells ex vivo. This cell cycle progression was previously described for malignant B cells stimulated by CD40L. 7, 32, 33 While we could observe a shift of the relative number of cells in S phase after BCR ligation in our study (data not shown), there are some conflicting results with regard to the effects of BCR engagement on survival and cell cycle progression of CLL cells. Engagement of surface IgM was described to elicit a strong survival program in B-CLL cells, which is associated with the inhibition of caspase activity and activation of NF-kB. 6 In contrast, McConkey et al 34 described in a small series of patients that in four of seven cases CLL cells underwent apoptosis upon IgM engagement. It is speculated that differences in antibody reagents and concentration of CLL cells in culture contribute to the contradictory results. Furthermore, different effects were observed for sIgD and sIgM crosslinking in dependence of CD38 expression on CLL cells. 35 Response to IgM binding in CLL cells can be modulated by other cofactors like CD6 engagement. 36 CD5 is another molecule associated with the human BCR complex in CLL B cells and in a small subpopulation of normal B cells. 37 CD5 ligation results in heterogeneous apoptotic responses with death signaling operating via CD79 and CD38. 38 In a bovine leukemia model resulting in persistent lymphocytosis, the CD5 molecule was dissociated from the BCR in CD5 + B cells. 39 This disrupted CD5-BCR interaction resulted in decreased apoptosis and increased survival after a-sIgM stimulation. Finally, one important mechanism for inhibiting signaling for apoptosis in B-CLL after ligation of the BCR might be an overexpression of the alternative transcript of CD79b (DeltaCD79b). [40] [41] [42] Resulting survival signals in B-CLL are then mediated via protein kinase C, phosphatidylinositol 3-kinase and the serine/threonine kinase Akt. 43, 44 Whatever the mechanism of these antiapoptotic effects after BCR ligation might be, it enables an almost selective transduction of malignant B-CLL cells after BCR stimulation by rAAV, while normal B-lymphocytes were shown to be driven in apoptosis by the same stimulus.
In our series of patients, we have observed differing responses to IgM ligation with regard to HSPG upregulation and rAAV transduction efficiency. Recently, it was demonstrated that differential signaling via sIgM is closely associated with the V H gene status: cases with unmutated V H genes showed increased tyrosine phosphorylation including activation of Syk. 45 Expression of ZAP-70 was shown to be closely correlated with an unmutated IgV H status in B-CLL and with an unfavorable prognosis of the disease. 9, 14 In other studies, there was also an association observed between CD38 expression and a-IgM responsiveness. 10 Importantly, recent data indicate that ZAP-70 expression is associated with enhanced signal transduction via the BCR complex. 13 In our study, high levels of ZAP-70 as an indicator of an efficient BCR signaling were highly predictive for a better transduction efficiency by rAAV when the gene transfer was accomplished by stimulation of the BCR. Therefore, a screening analysis for ZAP-70 expression should allow a prediction whether individual CLL samples will be amenable to AAV-based gene transduction.
AAV transduction after CD40L stimulation was shown to be enhanced by the addition of CpG oligodeoxynucleotides (CpG-ODNs); however, CpG-ODNs could not replace the strong stimulatory capacity of CD40L for efficient AAV infection. 18 CpG-ODNs were also shown to enhance the capacity of recombinant adenovirusmediated gene transfer in a murine B-cell lymphoma model. 46 Interestingly, normal and malignant human Blymphocytes express a distinct toll-like receptor repertoire including TLR9 and TLR10, both of them being induced upon engagement of the BCR. 47, 48 It can be speculated that combined use of a-sIg and CpG-ODNs might be optimal for responsiveness of B-CLL cells for AAV infection without the need for CD40 receptor activation on leukemic cells.
Besides recombinant adenovirus that was already successfully established as a gene transfer vehicle for CD40L in a phase I clinical trial, 17 our improved feederfree AAV transduction protocol might become ready for clinical testing in the near future. In contrast to other transduction systems for B-CLL, rAAV has advantageous safety features without the threat of the potential activation of oncogenic sequences as described for EBV-derived transduction systems. 49 Viral mutants with modified tropism based on a selection process within a library of AAV clones with randomly modified capsids, the AAV display, allow to generate CLL-specific targeting vectors, but safety issues of these vectors have to be addressed before entering the clinic. 50 We have shown that after infection with AAV particles encoding CD40L, the immune accessory molecule CD80 was expressed on infected CLL cells, but also on noninfected bystander leukemia B cells. Similar results were previously described for an adenoviral transfer system and also for AAV vectors being used after prestimulation of CLL cells by CD40L-expressing feeder cells. 7, 15 Using rAAV as a mainly nonimmunogenic vector transfer system together with engagement of the BCR, it might be possible to define CLL-specific T-cell responses in the context of a clinical vaccination protocol based on ex vivo CD40L-transduced CLL cells.
Materials and methods
Patients, cells, and cell culture After informed consent, peripheral blood was obtained from patients satisfying diagnostic criteria for B-CLL. 51 Mononuclear cells were isolated on a Ficoll/Hypaque (Seromed, Berlin, Germany) density gradient by centrifugation and depleted from monocytes by adherence to plastic tissue culture flasks. More than 98% of isolated cells coexpressed CD5 and CD19, as assessed by flow cytometry. Patients were either untreated or had not received cytoreductive treatment for a period of at least 1 month before investigation. Human tonsillar lymphocytes were isolated from tonsils as described previously. 52 HeLa cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA), 293 cells were a gift from M Lohse, University of Wü rzburg, Germany. Cells were cultured at 371C in 5% CO 2 in air, in the culture medium consisting of DMEM (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (FCS; Biochrom), 2 mM L-glutamine (Biochrom), 100 U/ml penicillin (Biochrom), and 100 mg/ml streptomycin (Biochrom).
HeLa/SF cells transfected with human CD40L cDNA were produced and cultured as described previously. 53 Before the addition of B-CLL cells, the feeder layers were washed twice with phosphate-buffered saline (PBS), and tumor cells were cultured at 2 Â 10 6 cells/ml in Iscove's medium (GibcoBRL) supplemented with 20% heatinactivated FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. For functional assays, CLL cells were harvested, purified by Ficoll density-gradient centrifugation, washed and analyzed by flow cytometry.
Antibodies and reagents
Immunophenotyping was performed with the following monoclonal antibodies (mAbs) conjugated with fluorescein isothiocyanate, phycoerythrin (PE), or PE cyanine 5 (PE-Cy5): CD5, CD19 (both from Beckman Coulter, Krefeld, Germany), CD38, CD80, anti-IgM, anti-IgG, antiIgA (BDPharMingen, Heidelberg, Germany). Fluorescein-conjugated mAbs specific for murine CD40L were purchased from BDPharMingen and expression was controlled by an isotype hamster IgG 3 mAb (BDPharMingen). For the detection of HSPG, cells were stained with fluorescein-conjugated anti-heparan sulfate (10E4 epitope) mAb (Seikagaku America, MA, USA) or a murine IgM isotype control (BDPharMingen). As described previously, intracellular ZAP-70 expression in B-CLL cells was detected with an anti-ZAP-70-specific mAb (Upstate Biotechnology, Waltham, MA, USA) after cells were fixed and permeabilized with use of 4% formaldehyde (Sigma-Aldrich, St Louis, MO, USA) and 0.4% saponin (Sigma-Aldrich). 54 Heparin (10 000 U/ml; Braun, Melsungen, Germany) was used for blocking experiments with infectious AAV.
Rabbit anti-human Ig Immunobead R reagents with heavy-chain specificity for human IgG, IgA or IgM were used for BCR crosslinking and were purchased from Irvine Scientific, Santa Ana, CA, USA. Immunobead R reagents consist of purified antibodies covalently bound to micron-sized hydrophilic polyacrylamide beads.
RNAse (Boehringer Mannheim, Mannheim, Germany) and propidium iodide (Bender MedSystems Diagnostic GmbH, Vienna, Austria) were used for cell cycle analysis. The fraction of apoptotic cells was determined by annexin binding assay using annexin V, annexin buffer, and propidium iodide (Bender MedSystems Diagnostic).
Plasmids
The adenoviral pXX6 plasmid was a friendly gift from R Samulski and described previously. 55 The constructs pAAV/EGFP coding for the EGFP and pAAV/mCD40L containing the murine CD40L encoding gene were described previously. 7 The helper plasmid pXR1 containing the serotype-specific capsid coding domains (cap) of AAV-1 in the context of AAV-2-specific replication genes (rep) was a friendly gift from JE Rabinowitz, University of North Carolina, Chapel Hill, USA, and was used for crosspackaging of AAV-1-specific virions coding for EGFP. 56 The plasmid for the AAV mutant RGD4C with a specific RGD motif, which allows AAV to enter a cell by a heparan sulfate-independent cell entry mechanism, was described previously. 12 rAAV vector production and purification Packaging of rAAV vectors was performed by cotransfection of 293 cells by calcium phosphate with a total of 37.5 mg vector plasmid (pAAV/EGFP or pAAV/ mCD40L), packaging plasmid pRC, and adenoviral plasmid pXX6 (kindly provided by J Samulski) at a 1 : 1 : 1 molar ratio. 55, 57 Purification was achieved by ammonium sulfate precipitation followed by iodixanol gradient centrifugation. 58, 59 This resulted in an infectious AAV/EGFP and AAV/CD40L titer of 1À5 Â 10 9 /ml.
AAV transduction
A total of 5 Â 10 5 primary CLL cells per well (96-well plate) were incubated in a total of 50 ml IMDM medium supplemented with 20% FCS and infectious AAV was added resulting in an MOI of 50. For indicated experiments Immunobead R reagent was added to leukemic cells together with rAAV. Cells were incubated for 2 h at 371C in 5% CO 2 in air, followed by several washing steps. Infected cells were transferred on an g-irradiated feeder layer expressing CD40L (HeLa/SF) in some experiments, as indicated, and 150 ml Iscove's medium was added.
Flow cytometry
At 48 h after AAV transduction, CLL cells were harvested, purified by Ficoll density-gradient centrifugation, and washed. Specific, directly conjugated antibodies were applied to cells for 30 min in PBS, 4% FCS, 0.1% sodium acide, 20 mM HEPES, and 5 mM EDTA pH 7.3 on ice and washed. Nonspecific binding was controlled by incubation with isotypic controls (murine isotype IgG 1 mAb and hamster isotype IgG 3 mAb, BDPharMingen). Fluorescence was measured with a Coulter Epics XL-MCL (Beckman Coulter, Krefeld, Germany). A minimum of 5000 cells were analyzed for each sample. The percentage of positive cells was defined as the fraction beyond the region of 99% of the control-stained cells. Data were analyzed with the use of WinMDI2.8 FACS software. The MFIR was calculated to compare the relative staining intensities of two or more cell populations. 15 AAV gene transfer into B-CLL by BCR-stimulation DM Kofler et al
Transactivation assay
CD40L-transduced or mock-infected B-CLL cells were prelabeled with a green fluorescent dye (CellTrackert Green CMFDA, Molecular Probes) at a concentration of 1 mM for 15 min at 371C. After extensive washing, labeled stimulator cells were cocultured with noninfected, nonstained CLL cells from the same patient at 371C for another 48 h. Expression of CD80 on noninfected, nonlabeled naive CLL cells was assessed by PE-conjugated anti-CD80 mAb (Beckman Coulter).
Statistics
Statistical associations between dependent subgroups were analyzed by the t-test for paired samples; statistical associations between independent subgroups were carried out using the t-test for unpaired samples. 
